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Screening 
RJC Steele 
It is well established by randomised controlled trials that screening for colorectal cancer 
(CRC) using guaiac faecal occult blood tests (gFOBTs), and, by implication, the newer faecal 
immunochemical tests (FITs) for haemoglobin can reduce disease specific mortality by 
means of early detection1.  In addition, it been shown that endoscopic screening in the form 
of flexible sigmoidoscopy can not only reduce mortality from CRC, but also, by the detection 
of adenomas, it is an effective means of reducing disease incidence2.  Both modalities are 
now employed in the UK for population screening, and the older gFOBT is now being 
replaced by FIT.   
FIT has advantages over gFOBT in that it is specific for human haemoglobin, it is easier to do 
and therefore associated with higher participation rates and it is quantitative so that the 
threshold for triggering a colonoscopy can be set at a level that is in keeping with current 
colonoscopy capacity3.  When the FIT threshold is set at the same analytical sensitivity as 
gFOBT (i.e. produces the same positivity rate in the population) it performs better that 
gFOBT in the detection of adenomas4, thus enhancing the screening programme’s ability to 
prevent colorectal cancer. 
In terms of clinical impact, the screening programme has increased the proportion of CRCs 
diagnosed at an early stage.  In a mature gFOBT programme, which consists of a 
combination of prevalence and incidence screening, around 35 % of screen-detected 
cancers are diagnosed at stage A as opposed to 11% in the symptomatic population5. Indeed 
in the region of 16 % of screen-detected cancers are polyp cancers, and are completely 
removed by colonoscopic polypectomy, usually at the same time as the colonoscopy 
organised in response to a positive gFOBT or FIT result.  Flexible sigmoidoscopy screening 
also picks up early cancers, but its main strength lies in its ability to identify adenomas2. 
One result of this screening activity is to present the endoscopic and surgical services with 
an increasing number of early cancers and polyps, many of the latter being complex, and 
challenging for both endoscopists and pathologists. Thus, although this has significant 
advantages in terms of survival it adds to the clinical dilemmas that SPECC was set up to 
address. In addition, of course, it results in a degree of overdiagnosis i.e. some patients will 
be diagnosed with disease from which they were never destined to die.  
Screening programmes in the UK are not perfect; the sensitivities at which gFOBT and FIT 
operate in order to avoid overwhelming the colonoscopy services mean that there are a 
significant number of interval cancers5, which, in the vast majority of cases, are undoubtedly 
cancers that were missed by the most recent screening test. For this reason, there is 
worldwide interest in developing tests for CRC that are more sensitive and specific than 
those in current use.  
Of course, colonoscopy as a screening test is highly sensitive (few false negatives) and 
specific (false positives are extremely rare).  However, problems with using colonoscopy in 
this context are that it is expensive, requires excellent bowel preparation, demands a large, 
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highly skilled workforce, is associated with relatively low uptake in the general population 
and carries a measurable morbidity and mortality.  Because of these uncertainties, although 
colonoscopy is widely employed as an “on demand” screening test, especially in North 
America, its utility in population screening is currently being tested in at least four RCTs, 
which will take several years to report6.  CT colography has also been promoted for 
population screening7, but has failed to gain traction as a first line test. 
 
Given the imperfections of blood in stool tests and endoscopy, a great deal of effort has 
gone into developing novel tests. Identification of mutated DNA in faeces shed from the 
surface of cancers and polyps has long been attractive, and indeed, a test that combines a 
panel of such markers with FIT has been marketed and approved by the FDA8.  However, 
although this is more sensitive than FIT, it is less specific, and, it has been argued that, by 
altering its threshold parameters, FIT alone can perform just as well9.  Blood tests have also 
been developed, such as those for DNA hypermethylation markers10, but again, none have 
been shown to outperform FIT. One of the most promising avenues is the study of volatile 
organic compounds, stimulated initially by the finding that dogs can be trained to recognise 
patients harbouring CRC by smelling breath or faeces11, but a clinically viable process has yet 
to be developed. The development of colon capsule endoscopy may also add to the 
screening armamentarium with time12. 
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